Compare INGR & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INGR | PTCT |
|---|---|---|
| Founded | 1906 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 6.1B |
| IPO Year | 1997 | 2013 |
| Metric | INGR | PTCT |
|---|---|---|
| Price | $113.63 | $71.42 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 17 |
| Target Price | ★ $134.57 | $73.76 |
| AVG Volume (30 Days) | 567.5K | ★ 1.3M |
| Earning Date | 02-03-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 10.01 | 8.94 |
| Revenue | ★ $7,262,000,000.00 | $1,779,150,000.00 |
| Revenue This Year | N/A | $129.80 |
| Revenue Next Year | $1.10 | N/A |
| P/E Ratio | $11.48 | ★ $8.11 |
| Revenue Growth | N/A | ★ 97.54 |
| 52 Week Low | $102.31 | $35.95 |
| 52 Week High | $141.78 | $87.50 |
| Indicator | INGR | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 57.80 | 34.81 |
| Support Level | $111.87 | $73.32 |
| Resistance Level | $117.01 | $77.87 |
| Average True Range (ATR) | 2.08 | 3.05 |
| MACD | 0.38 | -0.64 |
| Stochastic Oscillator | 68.24 | 13.31 |
Ingredion is an ingredients provider for the food, beverage, brewing, and animal nutrition industries. The company processes corn, tapioca, potatoes, stevia, grains, fruits, gums, and vegetables into value-added ingredients. The company sells specialty ingredients that include starch-based texturizers and natural alternative sweeteners such as stevia. Ingredion also sells commodity ingredients that include sweeteners, such as high-fructose corn syrup, and starches, such as those used for sustainable packaging, as well as plant-based proteins.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.